Biocon Biologics

Biocon Biologics is a fully-integrated pure-play biosimilars organization globally engaged in developing high-quality, affordable biosimilars aimed at expanding patient access to cutting-edge therapies. It develops and commercializes a differentiated portfolio of novel biologics, biosimilars, and complex small molecule APIs in India and several key global markets, as well as, generic formulations in the U.S. and Europe.

The company is driven by a belief that the pharmaceutical industry has a humanitarian responsibility to provide essential drugs to patients who are in need and to do so with the power of innovation.

Biocon Biologics headquartered in India, Asia, operates in the Biotechnology sector. The company focuses on Biotechnology and has secured $15.2B in funding across 24 round(s). With a team of 10001+ employees, Biocon Biologics is actively contributing to advancements in Biotechnology. Their latest funding round, Corporate Round - Biocon Biologics, raised $150.0M. Discover more about their projects, partnerships, and impact on our platform.